TY  - GEN
AU  - Glass,Bertram
AU  - Hasenkamp,Justin
AU  - Wulf,Gerald
AU  - Dreger,Peter
AU  - Pfreundschuh,Michael
AU  - Gramatzki,Martin
AU  - Silling,Gerda
AU  - Wilhelm,Christian
AU  - Zeis,Matthias
AU  - Görlitz,Anke
AU  - Pfeiffer,Sebastian
AU  - Hilgers,Reinhard
AU  - Truemper,Lorenz
AU  - Schmitz,Norbert
TI  - Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial
SN  - 1474-5488
PY  - 2014///0730
KW  - Adult
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - adverse effects
KW  - Combined Modality Therapy
KW  - Female
KW  - Graft vs Host Disease
KW  - etiology
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Lymphoma, Non-Hodgkin
KW  - mortality
KW  - Male
KW  - Middle Aged
KW  - Recurrence
KW  - Rituximab
KW  - Transplantation Conditioning
KW  - Transplantation, Homologous
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(14)70161-5
ER  -